Brokerage : IBK Securities
Analyst : Yisoo Jung, CFA
Investment Rating : BUY (Maintained)
Target Price : KRW 2,090,000 (Maintained)
Core Momentum : Full utilization of Plants 1–4 and favorable FX tailwinds support potential upward guidance revisions driven by H2 Plant 5 PPQ revenue contributions and US site consolidation.
📊 1. [Valuation & Key Financial Metrics]
- Rating & Target Price: BUY (Maintained) / Target Price KRW 2,090,000 (Maintained) (Closing price as of April 22, 2026: KRW 1,561,000)
- Market Data: KOSPI Index 6,417.93pt / Market Cap KRW 72.26 Trillion / Shares Outstanding 46,291,000 / Foreign Ownership 12.6% / Dividend Yield (2026F) 0.0% / Major Shareholders: Samsung C&T and 5 affiliates 74.31%, National Pension Service 6.68%
- Annual Financial Forecast (IBK Securities Estimates):
- 2026F: Revenue KRW 5.46 Trillion (+19.8% YoY), Operating Profit KRW 2.51 Trillion (+21.6% YoY), OPM 46.1%, Pre-tax Profit KRW 2.55 Trillion, Net Profit KRW 1.95 Trillion, EPS KRW 42,068 (+78.1% YoY), PER 37.1x, PBR 7.7x, ROE 23.2%, EV/EBITDA 24.9x
- 2027F: Revenue KRW 6.31 Trillion, Operating Profit KRW 2.91 Trillion, OPM 46.1%, Pre-tax Profit KRW 2.98 Trillion, Net Profit KRW 2.28 Trillion, EPS KRW 49,183, PER 31.7x, PBR 6.2x, ROE 21.7%, EV/EBITDA 21.6x
- 2028F: Revenue KRW 6.79 Trillion, Operating Profit KRW 3.11 Trillion, OPM 45.8%, Pre-tax Profit KRW 3.23 Trillion, Net Profit KRW 2.47 Trillion, EPS KRW 53,243, PER 29.3x, PBR 5.1x, ROE 19.1%, EV/EBITDA 20.2x
🚀 2. [Market Opportunities & Business Outlook]
- Q1 2026 Earnings Performance:
- Consolidated revenue reached KRW 1.26 Trillion (+25.8% YoY) and operating profit reached KRW 580.8 Billion (+35.0% YoY), meeting market consensus.
- Operating leverage expanded on sustained 100% utilization of Plants 1–4 and recognition of deferred Q4 revenues, driving OPM to 46.2% (+3.2%p YoY) and EBITDA to KRW 675.3 Billion (EBITDA margin 53.7%, +2.2%p YoY).
- Guidance Upside Potential & US Asset Integration:
- Full-year 2026 revenue is estimated at KRW 5.46 Trillion with operating profit at KRW 2.51 Trillion, comfortably tracking the baseline annual guidance range of 15%–20%.
- Additional revenue upside is anticipated from Q3 as the 60,000-liter US facility (acquired for USD 353 Million in late Q1) begins recognition, alongside top-line contributions from Plant 5 Process Performance Qualification (PPQ) batches in H2.
- FX rates remain advantageous, with April average levels (~1,490 KRW/USD) surpassing internal budget assumptions (~1,400 KRW/USD).
- Medium-Term Catalysts & Risk Factors:
- While near-term strike notices created temporary valuation overhang, resolving labor uncertainties is expected to shift focus toward US plant synergies, Plant 6 capacity expansion, and new modality diversification.
📝 Editor’s Comment (Perspective)
The analyst views Samsung Biologics as a leading global CDMO capable of demonstrating operating leverage across its fully utilized Plants 1–4, while building structural upside to exceed annual guidance via the consolidation of its US site and Plant 5 PPQ commercialization. The overarching perspective places strategic priority on the medium-term earnings expansion unlocked by acquiring US manufacturing assets and pursuing Plant 6 expansions rather than short-term market noise around union discussions.
To verify whether this investment thesis progresses as expected, investors should primarily monitor the actual consolidated revenue contributions from the US manufacturing facility in Q3, top-line recognition from Plant 5 PPQ batches in H2, and official upward revisions to annual revenue guidance. These developments can be verified through upcoming quarterly earnings releases, official company IR materials, regulatory filings on DART/KRX, and periodic disclosures.
📢 Disclaimer & Source
Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.
Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)
